Cargando…

Dendritic cell therapy for oncology roundtable conference

2-3 September 2010, Brussels, Belgium The Dendritic Cell Therapy for Oncology Roundtable Conference was organized by Reliable Cancer Therapies and moderated by Prof. Dr. Steven De Vleeschouwer. The organizer, Reliable Cancer Therapies, is a Swiss non-profit organization that provides information on...

Descripción completa

Detalles Bibliográficos
Autor principal: Tuyaerts, Sandra
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3027086/
https://www.ncbi.nlm.nih.gov/pubmed/21226916
http://dx.doi.org/10.1186/1476-8518-9-1
_version_ 1782197116102246400
author Tuyaerts, Sandra
author_facet Tuyaerts, Sandra
author_sort Tuyaerts, Sandra
collection PubMed
description 2-3 September 2010, Brussels, Belgium The Dendritic Cell Therapy for Oncology Roundtable Conference was organized by Reliable Cancer Therapies and moderated by Prof. Dr. Steven De Vleeschouwer. The organizer, Reliable Cancer Therapies, is a Swiss non-profit organization that provides information on evidence-based cancer treatments and funding for the development of a selection of promising cancer therapies. In order to be able to give valuable information about dendritic cell (DC) therapy to patients and physicians, the organizing committee felt it necessary to organize this conference to get an up-to-date status of the academic DC therapy field, collect ideas to guide patients towards clinical trials and to induce cross-fertilization for protocol optimization. In total, 31 experts participated to an in-depth discussion about the status and the future development path for dendritic cell vaccines. The conference started with general presentations about cancer immunotherapy, followed by comprehensive overview presentations about the progress in DC vaccine development achieved by each speaker. At the end of the meeting, a thorough general discussion focused on key questions about what is needed to improve DC vaccines. This report does not cover all presentations, but aims to highlight selected points of interest, particularly relating to possible limitations and potential approaches to improvement of DC therapies specifically, and also immunotherapeutic interventions in general terms.
format Text
id pubmed-3027086
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30270862011-01-27 Dendritic cell therapy for oncology roundtable conference Tuyaerts, Sandra J Immune Based Ther Vaccines Meeting Report 2-3 September 2010, Brussels, Belgium The Dendritic Cell Therapy for Oncology Roundtable Conference was organized by Reliable Cancer Therapies and moderated by Prof. Dr. Steven De Vleeschouwer. The organizer, Reliable Cancer Therapies, is a Swiss non-profit organization that provides information on evidence-based cancer treatments and funding for the development of a selection of promising cancer therapies. In order to be able to give valuable information about dendritic cell (DC) therapy to patients and physicians, the organizing committee felt it necessary to organize this conference to get an up-to-date status of the academic DC therapy field, collect ideas to guide patients towards clinical trials and to induce cross-fertilization for protocol optimization. In total, 31 experts participated to an in-depth discussion about the status and the future development path for dendritic cell vaccines. The conference started with general presentations about cancer immunotherapy, followed by comprehensive overview presentations about the progress in DC vaccine development achieved by each speaker. At the end of the meeting, a thorough general discussion focused on key questions about what is needed to improve DC vaccines. This report does not cover all presentations, but aims to highlight selected points of interest, particularly relating to possible limitations and potential approaches to improvement of DC therapies specifically, and also immunotherapeutic interventions in general terms. BioMed Central 2011-01-12 /pmc/articles/PMC3027086/ /pubmed/21226916 http://dx.doi.org/10.1186/1476-8518-9-1 Text en Copyright ©2011 Tuyaerts; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Meeting Report
Tuyaerts, Sandra
Dendritic cell therapy for oncology roundtable conference
title Dendritic cell therapy for oncology roundtable conference
title_full Dendritic cell therapy for oncology roundtable conference
title_fullStr Dendritic cell therapy for oncology roundtable conference
title_full_unstemmed Dendritic cell therapy for oncology roundtable conference
title_short Dendritic cell therapy for oncology roundtable conference
title_sort dendritic cell therapy for oncology roundtable conference
topic Meeting Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3027086/
https://www.ncbi.nlm.nih.gov/pubmed/21226916
http://dx.doi.org/10.1186/1476-8518-9-1
work_keys_str_mv AT tuyaertssandra dendriticcelltherapyforoncologyroundtableconference